Establishment of scientific cooperation with the M. Sklodowska-Curie National Institute of Oncology Gliwice Branch

8 November 2022 / 13:49

We are pleased to announce that on 08.11.2022 a Scientific Cooperation Agreement was signed between the M. Sklodowska-Curie National Cancer Institute Gliwice Branch and the consortium: Acellmed Sp. z o.o. and Silesian Park of Medical Technology Kardio-Med Silesia. The scientific cooperation will consist of verifying the therapeutic activity and specificity of action of the anti-acute myeloid leukemia (AML) drug being developed by the Acellmed – Silesian Park of Medical Technology Kardio-Med Silesia consortium on leukemic cells of AML patients treated at the M. Skłodowska-Curie National Cancer Institute Gliwice Branch.

The project to develop a drug against AML: “personalized liposome-based therapy for acute myeloid leukemia (OBS/AML) based on small inhibitory RNAs” is funded by the Office of the Marshal – Silesian Center for Entrepreneurship within the framework of the WSL ROP 1.2 competition.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    I consent to the processing of my personal data by Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o., 10C M. Curie-Skłodowskiej St., 41-800 Zabrze, KRS:0000396540, NIP:6482761515, Regon:242742607, as Data Controler in order to receive a response. I can withdraw my consent by submitting a statement to: The Data Controler has notified me that this consent does not affect the legality of the processing carried out on the basis of consent before its withdrawal.

    The information clause on the details of the processing is available here.

    Supporting partners: